Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 333 entries
Sorted by: Best Match Show Resources per page
5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.

The Canadian journal of hospital pharmacy

Jun JEJ, Kinkade A, Tung ACH, Tejani AM.
PMID: 28487578
Can J Hosp Pharm. 2017 Mar-Apr;70(2):113-119. doi: 10.4212/cjhp.v70i2.1643. Epub 2017 Apr 28.

BACKGROUND: Finasteride and dutasteride are competitive inhibitors of 5α-reductase enzymes and are commonly used to treat symptomatic benign prostatic hyperplasia (BPH).OBJECTIVE: To compare the efficacy and safety of finasteride and dutasteride in terms of clinically important outcomes.DATA SOURCES: A...

Cite
Jun JEJ, Kinkade A, Tung ACH, et al. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Can J Hosp Pharm. 2017;70(2):113-119doi: 10.4212/cjhp.v70i2.1643.
Jun, J. E. J., Kinkade, A., Tung, A. C. H., & Tejani, A. M. (2017). 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. The Canadian journal of hospital pharmacy, 70(2), 113-119. https://doi.org/10.4212/cjhp.v70i2.1643
Jun, Jennifer E J, et al. "5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis." The Canadian journal of hospital pharmacy vol. 70,2 (2017): 113-119. doi: https://doi.org/10.4212/cjhp.v70i2.1643
Jun JEJ, Kinkade A, Tung ACH, Tejani AM. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Can J Hosp Pharm. 2017 Mar-Apr;70(2):113-119. doi: 10.4212/cjhp.v70i2.1643. Epub 2017 Apr 28. PMID: 28487578; PMCID: PMC5407420.
Copy Download .nbib Format: NLM
Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia.

JAAD case reports

Donovan JC.
PMID: 27051778
JAAD Case Rep. 2015 Sep 30;1(6):353-5. doi: 10.1016/j.jdcr.2015.08.003. eCollection 2015 Nov.

No abstract available.

Cite
Donovan JC. Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. JAAD Case Rep. 2015;1(6):353-5doi: 10.1016/j.jdcr.2015.08.003.
Donovan, J. C. (2015). Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. JAAD case reports, 1(6), 353-5. https://doi.org/10.1016/j.jdcr.2015.08.003
Donovan, Jeff C. "Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia." JAAD case reports vol. 1,6 (2015): 353-5. doi: https://doi.org/10.1016/j.jdcr.2015.08.003
Donovan JC. Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. JAAD Case Rep. 2015 Sep 30;1(6):353-5. doi: 10.1016/j.jdcr.2015.08.003. eCollection 2015 Nov. PMID: 27051778; PMCID: PMC4809380.
Copy Download .nbib Format: NLM
Efficacy of Finasteride for Treating Patients with Androgenetic Alopecia who are Pileous in other Areas: A Pilot Study in Japan.

Indian journal of dermatology

Inadomi T.
PMID: 24700935
Indian J Dermatol. 2014 Mar;59(2):163-5. doi: 10.4103/0019-5154.127677.

BACKGROUND: Androgenetic alopecia (AGA) involves androgen-dependent hair loss and finasteride is an established treatment for the disease. However, reports of the influence of finasteride on hair growth in other areas of the body are lacking.AIMS: To investigate the effects...

Cite
Inadomi T. Efficacy of Finasteride for Treating Patients with Androgenetic Alopecia who are Pileous in other Areas: A Pilot Study in Japan. Indian J Dermatol. 2014;59(2):163-5doi: 10.4103/0019-5154.127677.
Inadomi, T. (2014). Efficacy of Finasteride for Treating Patients with Androgenetic Alopecia who are Pileous in other Areas: A Pilot Study in Japan. Indian journal of dermatology, 59(2), 163-5. https://doi.org/10.4103/0019-5154.127677
Inadomi, Toru. "Efficacy of Finasteride for Treating Patients with Androgenetic Alopecia who are Pileous in other Areas: A Pilot Study in Japan." Indian journal of dermatology vol. 59,2 (2014): 163-5. doi: https://doi.org/10.4103/0019-5154.127677
Inadomi T. Efficacy of Finasteride for Treating Patients with Androgenetic Alopecia who are Pileous in other Areas: A Pilot Study in Japan. Indian J Dermatol. 2014 Mar;59(2):163-5. doi: 10.4103/0019-5154.127677. PMID: 24700935; PMCID: PMC3969676.
Copy Download .nbib Format: NLM
Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?.

The Journal of clinical and aesthetic dermatology

Singh MK, Avram M.
PMID: 25584139
J Clin Aesthet Dermatol. 2014 Dec;7(12):51-5.

The use of finasteride for the treatment of male pattern hair loss has recently been the focus of media and internet attention for potential irreversible sexual dysfunction and severe depression. The purpose of this study was to perform a...

Cite
Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?. J Clin Aesthet Dermatol. 2014;7(12):51-5
Singh, M. K., & Avram, M. (2014). Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?. The Journal of clinical and aesthetic dermatology, 7(12), 51-5.
Singh, Meena K, and Avram, Marc. "Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?." The Journal of clinical and aesthetic dermatology vol. 7,12 (2014): 51-5.
Singh MK, Avram M. Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?. J Clin Aesthet Dermatol. 2014 Dec;7(12):51-5. PMID: 25584139; PMCID: PMC4285451.
Copy Download .nbib Format: NLM
Hair loss and regeneration performed on animal models.

Clujul medical (1957)

Orasan MS, Roman II, Coneac A, Muresan A, Orasan RI.
PMID: 27547051
Clujul Med. 2016;89(3):327-34. doi: 10.15386/cjmed-583. Epub 2016 Jul 28.

Research in the field of reversal hair loss remains a challenging subject. As Minoxidil 2% or 5% and Finasteride are so far the only FDA approved topical treatments for inducing hair regrowth, research is necessary in order to improve...

Cite
Orasan MS, Roman II, Coneac A, et al. Hair loss and regeneration performed on animal models. Clujul Med. 2016;89(3):327-34doi: 10.15386/cjmed-583.
Orasan, M. S., Roman, I. I., Coneac, A., Muresan, A., & Orasan, R. I. (2016). Hair loss and regeneration performed on animal models. Clujul medical (1957), 89(3), 327-34. https://doi.org/10.15386/cjmed-583
Orasan, Meda Sandra, et al. "Hair loss and regeneration performed on animal models." Clujul medical (1957) vol. 89,3 (2016): 327-34. doi: https://doi.org/10.15386/cjmed-583
Orasan MS, Roman II, Coneac A, Muresan A, Orasan RI. Hair loss and regeneration performed on animal models. Clujul Med. 2016;89(3):327-34. doi: 10.15386/cjmed-583. Epub 2016 Jul 28. PMID: 27547051; PMCID: PMC4990426.
Copy Download .nbib Format: NLM
Medical therapy for BPH: expanding our treatment paradigm?.

Prostate cancer and prostatic diseases

Nickel JC, Nickel DJ.
PMID: 12496855
Prostate Cancer Prostatic Dis. 1999 Jan;2:34-38. doi: 10.1038/sj.pcan.4500275.

Medical therapy for relief of symptoms of benign prostatic hyperplasia (BPH) is now a clinical reality. The challenge for urologists treating BPH with medical therapy is how to rationally employ the two proven classes of medications,the alpha blockers and...

Cite
Nickel JC, Nickel DJ. Medical therapy for BPH: expanding our treatment paradigm?. Prostate Cancer Prostatic Dis. 1999;2:34-38doi: 10.1038/sj.pcan.4500275.
Nickel, J. C., & Nickel, D. J. (1999). Medical therapy for BPH: expanding our treatment paradigm?. Prostate cancer and prostatic diseases, 234-38. https://doi.org/10.1038/sj.pcan.4500275
Nickel, J C, and Nickel, Dr J C. "Medical therapy for BPH: expanding our treatment paradigm?." Prostate cancer and prostatic diseases vol. 2 (1999): 34-38. doi: https://doi.org/10.1038/sj.pcan.4500275
Nickel JC, Nickel DJ. Medical therapy for BPH: expanding our treatment paradigm?. Prostate Cancer Prostatic Dis. 1999 Jan;2:34-38. doi: 10.1038/sj.pcan.4500275. PMID: 12496855.
Copy Download .nbib Format: NLM
Combination medical therapy for symptomatic benign prostatic hyperplasia.

The Canadian journal of urology

Savage SJ, Spungen AM, Galea G, Britanico J, Vapnek JM.
PMID: 11305957
Can J Urol. 1998 Aug;5(3):578-584.

PURPOSE: The purpose of this study was to evaluate treatment response to terazosin, finasteride, or a combination of both in men with symptomatic benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: Patients with BPH were consecutively enrolled from a clinical...

Cite
Savage SJ, Spungen AM, Galea G, et al. Combination medical therapy for symptomatic benign prostatic hyperplasia. Can J Urol. 1998;5(3):578-584
Savage, S. J., Spungen, A. M., Galea, G., Britanico, J., & Vapnek, J. M. (1998). Combination medical therapy for symptomatic benign prostatic hyperplasia. The Canadian journal of urology, 5(3), 578-584.
Savage, Stephen J., et al. "Combination medical therapy for symptomatic benign prostatic hyperplasia." The Canadian journal of urology vol. 5,3 (1998): 578-584.
Savage SJ, Spungen AM, Galea G, Britanico J, Vapnek JM. Combination medical therapy for symptomatic benign prostatic hyperplasia. Can J Urol. 1998 Aug;5(3):578-584. PMID: 11305957.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Prevention, complementary therapies, and new scientific developments in the field of prostate cancer.

Reviews in urology

Kantoff P.
PMID: 17021644
Rev Urol. 2006;8:S9-S14.

Prostate cancer prevention and therapies were reviewed in a recent update. Finasteride, a 5alpha reductase inhibitor, shows promise as a preventative; however, it may increase the incidence of high-grade cancer. There are ongoing studies regarding the positive effects of...

Cite
Kantoff P. Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. Rev Urol. 2006;8:S9-S14
Kantoff, P. (2006). Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. Reviews in urology, 8S9-S14.
Kantoff, Philip. "Prevention, complementary therapies, and new scientific developments in the field of prostate cancer." Reviews in urology vol. 8 (2006): S9-S14.
Kantoff P. Prevention, complementary therapies, and new scientific developments in the field of prostate cancer. Rev Urol. 2006;8:S9-S14. PMID: 17021644; PMCID: PMC1578719.
Copy Download .nbib Format: NLM
[Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma].

Hellenic journal of nuclear medicine

Grammaticos P.
PMID: 15841288
Hell J Nucl Med. 2004 Sep-Dec;7(3):146-8.

The upper normal limit of serum prostate specific antigen (PSA) of 4 ng/ml is positively evaluated since it discriminates a large percentage of patients having prostate cancer. The PSA limit of 2.5 ng/ml may be used accordingly for patients...

Cite
Grammaticos P. In Process Citation. [Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]. Hell J Nucl Med. 2004;7(3):146-8
Grammaticos, P. (2004). In Process Citation. [Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]. Hellenic journal of nuclear medicine, 7(3), 146-8.
Grammaticos, Philip. "In Process Citation." [Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]. Hellenic journal of nuclear medicine vol. 7,3 (2004): 146-8.
Grammaticos P. In Process Citation. [Diagnostic and prognostic value of serum prostate specific antigen in prostate carcinoma]. Hell J Nucl Med. 2004 Sep-Dec;7(3):146-8. Greek, Modern. PMID: 15841288.
Copy Download .nbib Format: NLM
A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis).

The Journal of urology

Schaeffer AJ.
PMID: 15711290
J Urol. 2005 Mar;173(3):845.

No abstract available.

Cite
Schaeffer AJ. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). J Urol. 2005;173(3):845
Schaeffer, A. J. (2005). A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). The Journal of urology, 173(3), 845.
Schaeffer, Anthony J. "A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis)." The Journal of urology vol. 173,3 (2005): 845.
Schaeffer AJ. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). J Urol. 2005 Mar;173(3):845. PMID: 15711290.
Copy Download .nbib Format: NLM
The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome.

Current urology reports

Donnell RF.
PMID: 15260931
Curr Urol Rep. 2004 Aug;5(4):298. doi: 10.1007/s11934-004-0054-2.

No abstract available.

Cite
Donnell RF. The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2004;5(4):298doi: 10.1007/s11934-004-0054-2.
Donnell, R. F. (2004). The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome. Current urology reports, 5(4), 298. https://doi.org/10.1007/s11934-004-0054-2
Donnell, Robert F. "The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome." Current urology reports vol. 5,4 (2004): 298. doi: https://doi.org/10.1007/s11934-004-0054-2
Donnell RF. The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2004 Aug;5(4):298. doi: 10.1007/s11934-004-0054-2. PMID: 15260931.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 333 entries